Research Analysts’ Weekly Ratings Updates for Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals (NASDAQ: APLS) recently received a number of ratings updates from brokerages and research firms: 4/2/2026 – Apellis Pharmaceuticals was downgraded by Roth Mkm from “strong-buy” to “hold”. 4/2/2026 – Apellis Pharmaceuticals had its price target raised by Mizuho from $20.00 to $41.00. They now have a “neutral” rating on the stock. 4/1/2026 – […]
7 Apr 22:36 · The Markets Daily